Table 1.
Baseline characteristics of the study participants by biomarker group
| All (N=763) |
A–N– (N=202) |
A+N– (N=118) |
A–N+ (N=229) |
A+N+ (N=214) |
|
|---|---|---|---|---|---|
| Age, y | |||||
| Median (IQR) | 77 (74, 82) | 75 (72, 78) | 76 (72, 81) | 78 (75, 84) | 80 (77, 84) |
| Range | 70 to 95 | 70 to 92 | 70 to 93 | 70 to 93 | 70 to 95 |
| Sex, n (%) | |||||
| Male | 414 (54%) | 91 (45%) | 61 (52%) | 136 (59%) | 126 (59%) |
| Female | 349 (46%) | 111 (55%) | 57 (48%) | 93 (41%) | 88 (41%) |
| Education, median (IQR), y | 14 (12, 16) | 14 (12, 17) | 14 (12, 17) | 14 (12, 17) | 14 (12, 16) |
| Education level, n (%) | |||||
| High school or less | 244 (32%) | 68 (34%) | 36 (31%) | 77 (34%) | 63 (29%) |
| Some college | 519 (68%) | 134 (66%) | 82 (69%) | 152 (66%) | 151 (71%) |
| APOE status, n (%) | |||||
| Carrier | 202 (26%) | 37 (18%) | 57 (48%) | 30 (13%) | 78 (36%) |
| Non-carrier | 561 (74%) | 165 (82%) | 61 (52%) | 199 (87%) | 136 (64%) |
| Cognitive z scores, median (IQR)* | |||||
| Global | 0.0 (−0.7, 0.7) | 0.3 (−0.4, 1.0) | 0.1 (−0.6, 0.8) | 0.0 (−0.6, 0.7) | −0.3 (−1.0, 0.4) |
| Memory | 0.0 (−0.8, 0.7) | 0.1 (−0.5, 0.9) | 0.1 (−0.5, 0.8) | 0.0 (−0.7, 0.7) | −0.3 (−1.1, 0.4) |
| Attention | 0.1 (−0.6, 0.7) | 0.4 (−0.2, 1.0) | 0.2 (−0.5, 0.7) | 0.1 (−0.7, 0.6) | −0.3 (−0.9, 0.5) |
| Language | 0.1 (−0.6, 0.7) | 0.3 (−0.4, 0.9) | 0.1 (−0.5, 0.8) | 0.1 (−0.5, 0.7) | −0.2 (−0.8, 0.4) |
| Visuospatial | 0.1 (−0.6, 0.7) | 0.2 (−0.6, 0.9) | 0.0 (−0.7, 0.7) | 0.2 (−0.5, 0.7) | −0.1 (−0.8, 0.5) |
| Follow-up, y† | |||||
| Median (IQR) | 4.4 (2.4, 6.5) | 5.1 (2.7, 6.6) | 5.1 (2.6, 6.7) | 5.1 (2.5, 6.5) | 3.8 (1.5, 6.2) |
| Range | 0.3 to 11.4 | 0.6 to 9.0 | 1.0 to 10.3 | 1.1 to 11.4 | 0.3 to 11.0 |
| No. progressed to MCI or dementia | 159 | 17 | 22 | 49 | 71 |
| No. died before MCI or dementia | 39 | 5 | 2 | 10 | 22 |
*
Cognitive domain z scores are averages 3 tests for memory, 2 tests for attention, 2 tests for language, and two tests for visuospatial normed to subjects in the study. The global domain score is an average of four domains normed to subjects in the study.
†
Follow-up calculated as time from baseline to MCI or death within 15 months of last visit. Some individuals died before a return visit.